Ramiro Sanchez - Feb 6, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Medical Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Feb 6, 2023
Transactions value $
$0
Form type
4
Date filed
2/8/2023, 07:25 PM
Previous filing
Feb 11, 2022
Next filing
Dec 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +97.7K $0.00 97.7K Feb 6, 2023 Common Stock 97.7K $34.41 Direct F1
transaction CERE Restricted Stock Units Award $0 +24.8K $0.00 24.8K Feb 6, 2023 Common Stock 24.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney